Clearstead Advisors, LLC Madrigal Pharmaceuticals, Inc. Transaction History
Clearstead Advisors, LLC
- $6.44 Billion
- Q4 2024
A detailed history of Clearstead Advisors, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Clearstead Advisors, LLC holds 58 shares of MDGL stock, worth $19,813. This represents 0.0% of its overall portfolio holdings.
Number of Shares
58
Previous 44
31.82%
Holding current value
$19,813
Previous $9,000
88.89%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding MDGL
# of Institutions
336Shares Held
22.3MCall Options Held
960KPut Options Held
940K-
Janus Henderson Group PLC London, X02.21MShares$754 Million0.36% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$698 Million38.14% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$693 Million9.12% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$681 Million10.03% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$675 Million6.75% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.84B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...